In 1933, the Glass-Steagall Act separated commercial banking from investment banking to stop the conflicts of interest that helped trigger the Great Depression. It was a structural fix for a structural problem: too much power concentrated inside vertically integrated financial conglomerates, hidden behind internal walls the public couldn’t see.
Today, the U.S. healthcare system is showing the same warning signs — and the Cannabis sector is the clearest modern case study of how these incentives play out.
A modern Glass-Steagall for healthcare would restore transparency, reduce conflicts of interest, and protect personal choice in an increasingly consolidated system.
📈 The Vertical Integration Problem
Healthcare conglomerates now combine insurance, pharmacy benefit managers (PBMs), pharmacies, data clearinghouses, clinics, and physician groups under one corporate umbrella. This creates a closed loop where the same company can:
- set the price
- approve the service
- process the claim
- own the clinic
- own the pharmacy
- and pay itself
Members of Congress — including Rep. Alexandria Ocasio‑Cortez — have begun comparing this structure to the pre‑Glass-Steagall banking system. The concern is not ideological; it’s mechanical. When the same entity controls every step of the pathway, the public loses visibility and choice.
💰 When Profit Controls the Pathway
Vertical integration rewards behaviours that maximise shareholder value, not patient outcomes:
- narrowing networks
- denying claims
- acquiring competitors
- controlling supply chains
- setting internal transfer prices
- reducing independent providers
This is the same pattern that destabilised finance in the early 20th century. Glass–Steagall broke the loop. Healthcare has no equivalent.
🔍 Case Study: Cannabis and the Limits of Corporate Ownership
Cannabis exposes the structural tension at the heart of modern healthcare consolidation.
❌ A plant cannot be owned.
Pharmaceutical and insurance business models rely on:
- patents
- exclusive rights
- proprietary formulations
- billable, codified treatments
Cannabis in its natural form does not fit this model. It cannot be patented as a whole plant, and it competes with high‑margin pharmaceutical products. This creates a strong incentive to:
- push Cannabis into prescription‑only channels
- favour synthetic or patented analogues
- restrict low‑cost, herbal access
- regulate the plant in ways that benefit corporate intermediaries
🔬 Recent developments reinforce this pattern:
- Schedule III reclassification
- pharmaceutical acquisitions and investment
- crackdowns on hemp and cannabinoids
- patent‑driven pharmaceutical pathways
- insurance‑linked prescribing models
- uncertainty around the Affordable Care Act
Together, these trends shift Cannabis from a community‑driven herbal product to a corporate‑controlled medical commodity.
🇦🇺 Australia shows the same structural logic.
Cannabis prescriptions in Australia are already integrated into the pharmaceutical supply chain:
- doctors prescribe
- pharmacies dispense
- insurers and regulators shape access
- corporate suppliers dominate the market
This demonstrates that the structural incentives are not uniquely American — they are systemic to any healthcare system where corporate consolidation shapes the pathway.
⚖️ State vs Federal Fracture Lines
Just as banking once suffered from inconsistent rules across states, healthcare and drug policy now operate in a patchwork:
- state‑legal Cannabis vs federal prohibition
- state insurance mandates vs federal exemptions
- state‑regulated clinics vs federal enforcement
- ICE actions reveal gaps in federal health protections
These contradictions create systemic fragility — the same kind that Glass-Steagall was designed to resolve.
🏛️ Why a Modern Glass-Steagall Matters
A structural separation law for healthcare could:
- break up vertically integrated healthcare conglomerates
- separate insurers from PBMs, pharmacies, and physician groups
- restore transparency
- reduce conflicts of interest
- protect independent providers
- prevent corporate capture of emerging health markets (including cannabis)
Glass-Steagall didn’t fix banking culture — it fixed the structure. Healthcare needs the same treatment.
🎤 FAQ
👉 Isn’t this just about U.S. drug policies?
No. The U.S. is the most visible example because of its scale and political influence, but the underlying issue is vertical integration, not geography. Australia, Canada, the U.K., and the EU are all experiencing similar consolidation patterns in healthcare and pharmaceuticals.
Cannabis prescriptions being routed through pharmacies in Australia is a clear example of how herbal products become absorbed into corporate medical pathways.
👉 How does this information apply to me?
If you live in any country where:
- insurers influence treatment
- pharmacies are corporatised
- pharmaceutical companies shape regulation
- Cannabis access is medicalised
- healthcare data is centralised
…then the same structural incentives are already operating around you. This affects price, access, choice, and the future of herbal and community‑based healthcare.
👉 What can we do to make systemic changes?
Systemic problems require structural solutions. The most effective actions include:
- supporting transparency laws
- advocating for separation between insurers, PBMs, and providers
- protecting herbal and non‑patentable medicines from over‑medicalisation
- strengthening independent clinics and pharmacies
- demanding clear reporting on corporate ownership and conflicts of interest
- supporting policy proposals that limit vertical integration
Public pressure created Glass-Steagall in 1933. Public pressure can create a healthcare equivalent today.
📚 References
- The Hill – Too big to care: It is time for a Glass-Steagall Act for health care — These vertically integrated healthcare giants create and benefit financially from conflicts of interest that harm patients, providers and taxpayers.
- Becker’s – ‘Vertical integration is destroying people’s ability to access care’: Payer CEOs face bipartisan congressional grilling — Lawmakers zeroed in on the growth of vertically integrated health conglomerates that own insurance companies, pharmacy benefit managers, physician practices and pharmacies under one umbrella.
- Hayden Rooke-Ley – Medicare Advantage and Vertical Consolidation in Health Care — Health insurance and retail conglomerates are rapidly acquiring providers, from primary care practices and surgery centers to home-based and post-acute care.
Manifesto – Interpreting the plant, the whole plant, and nothing but the plant.
✨ Topic Cluster
2. Legalisation Pathways & Structural Separation: Examining pathways to Cannabis legalisation, including descheduling, regulatory models, political incentives, and the structural reforms needed for a functional post‑prohibition system.
🏛️ Pillar Content
- Australia’s Road to Full Legalisation — A clear, evidence‑based roadmap to full Cannabis legalisation in Australia, explaining descheduling, roadblocks, terminology, and the path beyond regulated markets.
- Cannabis Pathway Divide After Rescheduling — How rescheduling reshapes the cannabis pathway debate, deepening the split between patented products and herbal whole‑plant medicine.
- Cannabis Policy Follows The Money — From Stoner Sloth to Big Pharma: What Changing Incentives Reveal About Law, Trust, and Reform for Cannabis Policy
- The Dream of Free Weed vs. The Nightmare of Reality — The dream of Cannabis freedom collides with outdated treaties, Big Pharma lobbying, and political reluctance.
- Hemp Seed Laws, Limits, and the Case for Reform — Australia regulates hemp seed as food but treats it as a risk. We explain the laws, compliance pressures, and why national reform is needed.
- The Radical Difference of Cannabis — Cannabis is radically misunderstood. This report explains how misclassification, misinformation, and political inertia shaped its history — and why the ECS changes everything.
- Driving For Change: Zero‑Tolerance With Exemptions — Driving reforms in NSW now accept that Cannabis presence is not impairment, yet still rely on zero‑tolerance with exemptions.
- Understanding Civil Rights — A clear, long‑form guide to how civil rights evolve and erode, covering history, autonomy, workplace rights, and modern structural restrictions.
- The Impairment Myth and Driving Laws — Driving laws fail because Cannabis is misclassified. We dissect the Impairment Myth and reveal how purpose‑based regulation restores clarity.
- How Misclassification Creates Confusion — Misclassification fuels confusion in policy. We explain why the rules don’t fit the plant & how evidence‑based law reform can overcome uncertainty.
📌 Related Reports
- Justice is Broken; Repairs are Long Overdue — Justice is overdue. The Pot Report exposes cracks in Cannabis law reform and the cost of delay to fix a broken system.
- Roadside Drug Test: When Medicine Breaks The Law — Australians have legal access to Cannabis for medical purposes — but roadside drug tests still take away their driver licence. Laws haven’t kept up.
- Fit‑for‑Duty Workplace Drug Testing Failure in Australia — Why impairment‑based testing protects safety better than presence testing in the Australian workplace.
- Medican: Your health is our business — This report explores how colonial power, corporate interests, and outdated legal frameworks have shaped policy, to the detriment of health.
- The Slippery Slope of Hemp Legislation — THC in hemp and the global implications for energy, agriculture, and policy. U.S. hemp laws continue to evolve, reshaping global debates.
- Decriminalisation vs Legalisation: Who Gets Your Money? — Decriminalisation and Legalisation — are often used interchangeably, yet they produce very different outcomes for people and the economy.
- Treaty Troubles Ahead with US Crackdown on Hemp — The treaty the U.S. helped architect is the ultimate legal backstop for prohibition. It treats all THC as controlled substances, without distinction.
- Corporate Dealers in Sheep’s Clothing — Corporate Cannabis wrapped itself in a Sheepshield. Now the patent has expired, tinctures are legal, and the wolf must face the people in its birthday suit.
- How Glass-Steagall Applies To Your Health — The Glass-Steagall Act is a model for the health system to reduce vertical integration.
- Owning the Cancer Treatment and the Plant — How expired patents, failed trials, and active claims still shape the future of cannabis‑based cancer treatment — and what this means for growers.
👉 This Article
How Glass-Steagall Applies To Your Health — The Glass-Steagall Act is a model for the health system to reduce vertical integration.